Cargando…

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy. Since monotherapy in cancer is generally not providing long-lasting clinical responses, we here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Goethem, Alan, Yigit, Nurten, Moreno-Smith, Myrthala, Vasudevan, Sanjeev A., Barbieri, Eveline, Speleman, Frank, Shohet, Jason, Vandesompele, Jo, Van Maerken, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593624/ https://www.ncbi.nlm.nih.gov/pubmed/28915653 http://dx.doi.org/10.18632/oncotarget.18982

Ejemplares similares

Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation
por: Van Goethem, Alan, et al.
Publicado: (2023)

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples
por: Van Goethem, Alan, et al.
Publicado: (2016)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

Identification of miRNAs contributing to neuroblastoma chemoresistance
por: Ayers, Duncan, et al.
Publicado: (2015)

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy
por: Van Roy, Nadine, et al.
Publicado: (2009)

Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11
por: De Preter, Katleen, et al.
Publicado: (2005)

Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2006)

Correction: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2007)

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
por: Lakoma, A, et al.
Publicado: (2015)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing
por: Decock, Anneleen, et al.
Publicado: (2016)

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
por: Decock, Anneleen, et al.
Publicado: (2012)

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma
por: Barbieri, Eveline, et al.
Publicado: (2013)

Restoration of the molecular clock is tumor suppressive in neuroblastoma
por: Moreno-Smith, Myrthala, et al.
Publicado: (2021)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
por: Rombaut, Dries, et al.
Publicado: (2019)

CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
por: Rihani, Ali, et al.
Publicado: (2014)

Author Correction: Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
por: Rombaut, Dries, et al.
Publicado: (2019)

A Constitutional Translocation t(1;17)(p36.2;q11.2) in a Neuroblastoma Patient Disrupts the Human NBPF1 and ACCN1 Genes
por: Vandepoele, Karl, et al.
Publicado: (2008)

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
por: Kumps, Candy, et al.
Publicado: (2013)

RNA pre-amplification enables large-scale RT-qPCR gene-expression studies on limiting sample amounts
por: Vermeulen, Joëlle, et al.
Publicado: (2009)

No evidence for involvement of SDHD in neuroblastoma pathogenesis
por: De Preter, Katleen, et al.
Publicado: (2004)

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma
por: Kumps, Candy, et al.
Publicado: (2010)

N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
por: Lammens, Tim, et al.
Publicado: (2012)

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming
por: Tao, Ling, et al.
Publicado: (2021)

SMARTer single cell total RNA sequencing
por: Verboom, Karen, et al.
Publicado: (2019)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2018)

MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
por: Gu, Lubing, et al.
Publicado: (2011)

Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action
por: Wang, Wei, et al.
Publicado: (2020)

Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2019)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
por: Tao, Ling, et al.
Publicado: (2022)

Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments
por: Rihani, Ali, et al.
Publicado: (2013)

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23
por: Michels, Evi, et al.
Publicado: (2008)

Immunohistochemical localization of mdm-2, p27(Kip1 )and bcl-2 in Warthin's tumor of the parotid gland
por: Abd-Elhamid, Ehab S, et al.
Publicado: (2009)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kheo1h6naipihj8nbb3m3e9usc